Evidence map›Paper›PMID 42573475›Full record

Trial reportEpilepsia2026

A Phase I study of the pharmacokinetics (PK), bioavailability, dose proportionality, safety, and tolerability of topiramate injection compared to Oral topiramate in healthy adult participants.

Adeboye O Bamgboye, James C Cloyd, Bernard D King, Lisa D Coles

Abstract readRandomized Controlled TrialClinical Trial, Phase IComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adeboye O BamgboyeDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-2681-0899
James C CloydDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0002-3607-6619
Bernard D KingMacnas Consulting International, Inc., New Bern, North Carolina, USA.
Lisa D ColesDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.ORCID https://orcid.org/0000-0003-3613-9904

Funding

CURx Pharmaceuticals, Inc.
6 · The paper itself

Abstract

This Phase I study evaluated the safety, tolerability, and pharmacokinetics of a 30-min topiramate injection (intravenous [IV] TPM) infusion compared with oral topiramate (oral TPM) in healthy adult participants. In this randomized, open-label, dose escalation, crossover study with 37 healthy participants received single doses of 50, 100, or 200 mg of an oral TPM tablet and an IV TPM formulation, using sulfobutylether beta-cyclodextrin as a solubilizer and stabilizer, infused over 30 min, with a 12-day washout. Blood samples for pharmacokinetic assessments were collected at predose through 192 h post dose. Concentration-time data were analyzed using non-compartmental analysis, and IV TPM relative bioavailability was determined. Topiramate injection AUC

Indexed as

AnticonvulsantsFructoseTopiramateAdministration, OralAdolescentAdultArea Under CurveBiological AvailabilityCross-Over StudiesDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedYoung AdultAnticonvulsantsFructoseTopiramateAnti‐seizure medicationbridging therapyclinical trialepilepsytopiramate

Identifiers

PMID42573475
PMCPMC13675767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.